About navenibart Navenibart is an investigational YTE-modified monoclonal antibody inhibitor of plasma kallikrein, an established and safe mechanism, currently being evaluated in clinical trials for ...

Researchers are testing a fundamentally different strategy against neurodegenerative disease: instead of clearing protein deposits after they form, new experimental therapies aim to stop toxic protein ...

By Hugo Francisco de Souza A novel nasal booster approach may help close the gap between systemic vaccination and infection-blocking mucosal immunity, offering fresh insight into next-generation COVID ...

ADCs combine antibodies with drug payloads for targeted therapy, but complex manufacturing requires monitoring CQAs across multiple entities.

Divergent diagnostic criteria is raising concerns that some patients are being misdiagnosed and unnecessarily treated.

Avalo Therapeutics (NASDAQ:AVTX) is preparing to report phase IIb data in the second quarter of 2026 from its LOTUS trial evaluating AVTX-009 in hidradenitis suppurativa (HS), CEO Garry Neil said ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in ...

As an innovative subtype of invasive brain-computer interfaces (BCIs), the Endovascular Brain-Computer Interface (EBCI) enables electrode delivery to target brain regions via endovascular intervention ...

Guggenheim Securities Emerging Outlook: Biotech Summit 2026 February 12, 2026 9:30 AM ESTCompany ParticipantsJohn Butler ...

BackgroundAlzheimer's disease (AD) is the most common neurodegenerative disorder, characterized by progressive cognitive decline and memory impairment ...

Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...